X

Drug Profile

CRISPR-Cas3 based gene therapy - C4U Corporation/Healiva

Latest Information Update: 08 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator C4U Corporation; Healiva
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Epidermolysis bullosa

Most Recent Events

30 Oct 2023 C4U Corporation and Healiva agree to co-develop CRISPR-Cas3 based gene therapy for Epidermolysis bullosa
30 Oct 2023 Early research in Epidermolysis bullosa in Japan (Parenteral)
30 Oct 2023 Early research in Epidermolysis bullosa in Switzerland (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com